Objective: This pilot study was done to assess the
effectiveness of bronchial arterial infusion (BAI) as a therapeutic
modality for centrally located early-stage lung cancer.
Patients and methods: Seven patients who had endoscopically
evaluated, centrally located early-stage squamous cell lung carcinoma,
including three patients with synchronous multiple primary lung
cancers, were offered BAI with
cis-diamminedichloroplatinum (CDDP; dosage, 50 to 150
mg/body, 35 to 100 mg/m2), a radical therapeutic method, as
an alternative to a resection.
early-stage lesions showed complete remission within 1 to 6 weeks
(median, 3.3 weeks) after BAI. In the three patients with multiple lung
cancers, BAI was used to treat accessible early-stage lesions, although
a surgical resection was required for advanced lesions. Three of the
seven patients suffered from severe bronchial ulcers after BAI. Six of
the patients in the study had no disease relapse to date at a median
follow-up time of 19.8 months (range, 11 to 32 months), but the other
patient died of a pulmonary hemorrhage 3 months after BAI.
Conclusion: Based on our findings, BAI with CDDP should be
reappraised as an effective therapeutic modality for centrally located
early-stage lung cancer and as an acceptable primary
BAI = bronchial arterial infusion;
CDDP = cis-diamminedichloroplatinum;
PDT = photodynamic therapy